ribavirin

Summary

Summary: A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.

Top Publications

  1. pmc Boceprevir for untreated chronic HCV genotype 1 infection
    Fred Poordad
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    N Engl J Med 364:1195-206. 2011
  2. ncbi Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
  3. ncbi IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
    Vijayaprakash Suppiah
    Storr Liver Unit, University of Sydney, Sydney, Australia
    Nat Genet 41:1100-4. 2009
  4. ncbi Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
    Yasuhito Tanaka
    Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
    Nat Genet 41:1105-9. 2009
  5. pmc Boceprevir for previously treated chronic HCV genotype 1 infection
    Bruce R Bacon
    Saint Louis University School of Medicine, St Louis, Mo 63110 0250, USA
    N Engl J Med 364:1207-17. 2011
  6. ncbi Telaprevir for retreatment of HCV infection
    Stefan Zeuzem
    Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany
    N Engl J Med 364:2417-28. 2011
  7. ncbi Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    M P Manns
    Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, Germany
    Lancet 358:958-65. 2001
  8. pmc Response-guided telaprevir combination treatment for hepatitis C virus infection
    Kenneth E Sherman
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0595, USA
    N Engl J Med 365:1014-24. 2011
  9. ncbi Preliminary study of two antiviral agents for hepatitis C genotype 1
    Anna S Lok
    Department of Internal Medicine, Division of Gastroenterology, 3912 Taubman Center, SPC 5362, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    N Engl J Med 366:216-24. 2012
  10. ncbi Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study
    Andri Rauch
    University Clinic of Infectious Diseases, University Hospital Bern and University of Bern, Bern, Switzerland
    Gastroenterology 138:1338-45, 1345.e1-7. 2010

Detail Information

Publications344 found, 100 shown here

  1. pmc Boceprevir for untreated chronic HCV genotype 1 infection
    Fred Poordad
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    N Engl J Med 364:1195-206. 2011
    Peginterferon-ribavirin therapy is the current standard of care for chronic infection with hepatitis C virus (HCV). The rate of sustained virologic response has been below 50% in cases of HCV genotype 1 infection...
  2. ncbi Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
    ..We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic ..
  3. ncbi IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
    Vijayaprakash Suppiah
    Storr Liver Unit, University of Sydney, Sydney, Australia
    Nat Genet 41:1100-4. 2009
    ..Treatment of chronic HCV consists of a combination of PEGylated interferon-alpha (PEG-IFN-alpha) and ribavirin (RBV)...
  4. ncbi Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
    Yasuhito Tanaka
    Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
    Nat Genet 41:1105-9. 2009
    The recommended treatment for patients with chronic hepatitis C, pegylated interferon-alpha (PEG-IFN-alpha) plus ribavirin (RBV), does not provide sustained virologic response (SVR) in all patients...
  5. pmc Boceprevir for previously treated chronic HCV genotype 1 infection
    Bruce R Bacon
    Saint Louis University School of Medicine, St Louis, Mo 63110 0250, USA
    N Engl J Med 364:1207-17. 2011
    ..with hepatitis C virus (HCV) genotype 1 who do not have a sustained response to therapy with peginterferon-ribavirin, outcomes after retreatment are suboptimal...
  6. ncbi Telaprevir for retreatment of HCV infection
    Stefan Zeuzem
    Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany
    N Engl J Med 364:2417-28. 2011
    Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virologic response to therapy with peginterferon alfa plus ribavirin.
  7. ncbi Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    M P Manns
    Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, Germany
    Lancet 358:958-65. 2001
    A sustained virological response (SVR) rate of 41% has been achieved with interferon alfa-2b plus ribavirin therapy of chronic hepatitis C...
  8. pmc Response-guided telaprevir combination treatment for hepatitis C virus infection
    Kenneth E Sherman
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0595, USA
    N Engl J Med 365:1014-24. 2011
    Patients with chronic infection with hepatitis C virus (HCV) genotype 1 often need 48 weeks of peginterferon-ribavirin treatment for a sustained virologic response. We designed a noninferiority trial (noninferiority margin, -10...
  9. ncbi Preliminary study of two antiviral agents for hepatitis C genotype 1
    Anna S Lok
    Department of Internal Medicine, Division of Gastroenterology, 3912 Taubman Center, SPC 5362, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    N Engl J Med 366:216-24. 2012
    Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addition of multiple direct-acting antiviral agents to their treatment regimen.
  10. ncbi Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study
    Andri Rauch
    University Clinic of Infectious Diseases, University Hospital Bern and University of Bern, Bern, Switzerland
    Gastroenterology 138:1338-45, 1345.e1-7. 2010
    ..We performed a genome-wide association study to screen for host genetic determinants of HCV persistence and response to therapy...
  11. ncbi Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C
    Edward J Gane
    New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand
    N Engl J Med 368:34-44. 2013
    ..We evaluated sofosbuvir, an oral nucleotide inhibitor of HCV polymerase, in interferon-sparing and interferon-free regimens for the treatment of HCV infection...
  12. ncbi Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
    John G McHutchison
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 361:580-93. 2009
    Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately compared.
  13. ncbi Telaprevir for previously treated chronic HCV infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC, USA
    N Engl J Med 362:1292-303. 2010
    Patients with genotype 1 hepatitis C virus (HCV) who do not have a sustained response to therapy with peginterferon alfa and ribavirin have a low likelihood of success with retreatment.
  14. ncbi Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
    Hiromitsu Kumada
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Hepatol 56:78-84. 2012
    To evaluate the efficacy and safety of telaprevir in combination with peginterferon-α2b (PEG-IFN) and ribavirin (RBV) in patients with chronic hepatitis C.
  15. ncbi Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C
    Masao Honda
    Department of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan
    Gastroenterology 139:499-509. 2010
    Multiple viral and host factors are related to the treatment response to pegylated-interferon and ribavirin combination therapy; however, the clinical relevance and relationship of these factors have not yet been fully evaluated.
  16. pmc Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study
    Michael W Fried
    University of North Carolina at Chapel Hill, NC
    Hepatology 58:1918-29. 2013
    ..two different simeprevir (SMV) doses administered once-daily (QD) with pegylated interferon (Peg-IFN)-α-2a and ribavirin (RBV) in treatment-naïve patients with HCV genotype 1 infection...
  17. pmc Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin
    Jeanette J McCarthy
    Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina 27708, USA
    Gastroenterology 138:2307-14. 2010
    Patients with chronic hepatitis C virus (HCV) infections are treated with pegylated interferon and ribavirin (PEG-IFN/RBV), which is effective in less than 50% of those infected with HCV genotype 1...
  18. ncbi Mechanism of action of interferon and ribavirin in treatment of hepatitis C
    Jordan J Feld
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Building 31, Room 9A27, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 436:967-72. 2005
    ..treatment with IFN-alpha alone achieved only modest success, the addition of the broad-spectrum antiviral agent ribavirin greatly improved responses...
  19. ncbi Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients
    Ming Lung Yu
    Department of Internal Medicine, Kaohsiung Municipal Ta Tung Hospital, Kaohsiung, Taiwan
    Hepatology 53:7-13. 2011
    ..SNPs) near the interleukin-28B gene to the hepatitis C virus genotype 1 (HCV-1) response to peginterferon/ribavirin treatment. We aimed to explore the impact on the treatment outcomes of Asian HCV-2 patients...
  20. ncbi Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C
    Michael T Dill
    Department of Biomedicine, Hepatology Laboratory, University of Basel, Basel, Switzerland
    Gastroenterology 140:1021-31. 2011
    ..Preactivation of this endogenous IFN system is associated with nonresponse to pegylated IFN-α (pegIFN-α) and ribavirin. Genome-wide association studies have associated allelic variants near the IL28B (IFNλ3) gene with treatment ..
  21. ncbi Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients
    Manuel Romero-Gomez
    Hepatology Unit, Hospital Universitario de Valme, Sevilla, Spain
    Gastroenterology 128:636-41. 2005
    We evaluated the effect of insulin resistance and viral factors on sustained virological response in patients with chronic hepatitis C treated with peginterferon plus ribavirin.
  22. ncbi Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C
    Maria Grazia Rumi
    AM Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Universita degli Studi di Milano, Milan, Italy
    Gastroenterology 138:108-15. 2010
    b>Ribavirin (RBV) combined with either pegylated interferon (PegIFN) alpha2a or PegIFNalpha2b is the standard of care for chronic hepatitis C virus (HCV) infection...
  23. ncbi Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis
    Bart J Veldt
    Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Ann Intern Med 147:677-84. 2007
    ..Clinical outcomes of chronic hepatitis C infection in patients with advanced fibrosis include liver failure, hepatocellular carcinoma, and death...
  24. ncbi Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University, Durham, NC 27715, USA
    N Engl J Med 360:1827-38. 2009
    ..Telaprevir, a protease inhibitor specific to the HCV nonstructural 3/4A serine protease, rapidly reduced HCV RNA levels in early studies...
  25. ncbi Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
    Paul Y Kwo
    Department of Medicine, Division of Gastroenterology Hepatology, Indiana University School of Medicine, Indianapolis, IN 46202 5121, USA
    Lancet 376:705-16. 2010
    Peginterferon plus ribavirin achieves sustained virological response (SVR) in fewer than half of patients with genotype 1 chronic hepatitis C virus infection treated for 48 weeks...
  26. pmc Ribavirin can be mutagenic for arenaviruses
    Hector Moreno
    Centro de Biologia Molecular Severo Ochoa CSIC UAM, Consejo Superior de Investigaciones Cientificas CSIC, Campus de Cantoblanco, 28049 Madrid, Spain
    J Virol 85:7246-55. 2011
    ..An off-label use of the purine nucleoside analogue ribavirin (1-β-d-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide) is the only antiviral treatment currently available for ..
  27. ncbi Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Ann Intern Med 140:346-55. 2004
    Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C.
  28. ncbi Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 48:372-80. 2005
    ..1b do not achieve highly sustained virological response rates to combination therapy with interferon plus ribavirin. Non-virological responders (NVRs, namely ultimate resistant cases) who do not achieve HCV-RNA negativity during ..
  29. ncbi Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy
    Stephen A Harrison
    Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, San Antonio, TX 78234, USA
    Hepatology 52:864-74. 2010
    ..5 microg/kg/week with ribavirin (RBV) at 800 to 1400 mg/day, (2) PEG-IFN alfa-2b at 1...
  30. pmc Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients
    Giulia Marchetti
    Department of Medicine, Surgery and Dentistry, Clinic of Infectious Diseases and Tropical Medicine, University of Milan, San Paolo Hospital, Milan, Italy
    PLoS ONE 7:e32028. 2012
    ..We asked whether increased MT and immune activation may hamper anti-HCV response in HIV/HCV patients...
  31. ncbi ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C
    Jacques Fellay
    Institute for Genome Sciences and Policy, Center for Human Genome Variation, Duke University, Durham, North Carolina 27708, USA
    Nature 464:405-8. 2010
    ..The standard of care therapy combines pegylated interferon (pegIFN) alpha and ribavirin (RBV), and is associated with a range of treatment-limiting adverse effects...
  32. pmc Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response
    Jama M Darling
    University of North Carolina, Chapel Hill, NC 27599, USA
    Hepatology 53:14-22. 2011
    ..with sustained virological response (SVR) in patients with chronic hepatitis C treated with peginterferon and ribavirin. Quantitation of interferon-γ-inducible protein-10 (IP-10) may also differentiate antiviral response...
  33. ncbi Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection
    Christian M Lange
    Medizinische Klinik 1, Klinikum der J W Goethe Universität Frankfurt am Main, D 60590 Frankfurt am Main, Germany
    J Hepatol 55:322-7. 2011
    ..We therefore, aimed to explore the impact of donor and recipient genotypes of these polymorphisms on hepatitis C virus (HCV) liver graft reinfection...
  34. pmc Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients
    Tatsuo Miyamura
    Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan
    PLoS ONE 6:e28617. 2011
    ..signal transducer and activator of transcription (STAT) 1 in pretreated liver tissues, interleukin (IL) 28B polymorphism and treatment response in hepatitis C virus (HCV)-infected patients treated with peginterferon and ribavirin.
  35. ncbi Hepatitis C pharmacogenetics: state of the art in 2010
    Nezam H Afdhal
    Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Hepatology 53:336-45. 2011
    ..with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon-alfa and ribavirin. The same polymorphisms were subsequently associated with spontaneous clearance of HCV in untreated patients...
  36. ncbi Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C
    Yasuhito Tanaka
    Department of Virology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
    Hum Mol Genet 20:3507-16. 2011
    Hematologic abnormalities during current therapy with pegylated interferon and ribavirin (PEG-IFN/RBV) for chronic hepatitis C (CHC) often necessitate dose reduction and premature withdrawal from therapy...
  37. ncbi Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA
    Hepatology 38:645-52. 2003
    ..during the early weeks of treatment (early virologic response [EVR]) with pegylated interferon alfa-2b and ribavirin (PEG/R) in identifying patients who would not respond to therapy...
  38. ncbi Side effects of therapy of hepatitis C and their management
    Michael W Fried
    Division of Digestive Diseases, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Hepatology 36:S237-44. 2002
    Interferon and ribavirin combination therapy for chronic hepatitis C produces a number of well-described side effects that are dominated by fatigue, influenza-like symptoms, hematologic abnormalities, and neuropsychiatric symptoms...
  39. ncbi Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus
    Jean Michel Pawlotsky
    Department of Virology, Hopital Henri Mondor, Université Paris Est Créteil, France
    Hepatology 53:1742-51. 2011
    ..of chronic hepatitis C virus (HCV) infection is based on the combination of pegylated interferon-α and ribavirin. The recent development of direct-acting antiviral (DAA) molecules that are active on HCV, together with in ..
  40. ncbi Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients
    Christoph Sarrazin
    Medizinische Klinik 1, J W Goethe University Hospital, Frankfurt am Main, Germany
    J Hepatol 54:415-21. 2011
    Genetic variation in the interleukin 28B (IL28B) gene has been associated with the response to interferon-alfa/ribavirin therapy in hepatitis C virus (HCV) genotype 1-infected patients...
  41. pmc The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase
    Pieter Leyssen
    Rega Institute for Medical Research, Minderbroedersstraat 10, B 3000 Leuven, Belgium
    J Virol 79:1943-7. 2005
    It is not yet clear to what extent depletion of intracellular GTP pools contributes to the antiviral activity of ribavirin. Therefore, the antiviral activities of (i) ribavirin, (ii) its 5-ethynyl analogue, 5-ethynyl-1-beta-D-..
  42. ncbi Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection
    Stefan Zeuzem
    J W Goethe University Hospital, Frankfurt, Germany
    Gastroenterology 141:2047-55; quiz e14. 2011
    ..patients with hepatitis C virus (HCV) infection that do not include the combination of peginterferon alfa and ribavirin. We investigated the antiviral effect and safety of BI 201335 (an inhibitor of the NS3/4A protease) and BI ..
  43. ncbi Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system
    Kyoko Mori
    Department of Tumor Virology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Virus Res 157:61-70. 2011
    b>Ribavirin (RBV) is a potential partner of interferon (IFN)-based therapy for patients with chronic hepatitis C...
  44. ncbi IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population
    Lourianne N Cavalcante
    Department of Medicine, Federal University of Bahia, Salvador, Bahia, Brazil
    Liver Int 32:476-86. 2012
    ..IL28B polymorphisms are predictors of therapy response in hepatitis C virus (HCV) patients. We do not know whether they are markers of treatment response in admixed populations or not...
  45. ncbi Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C
    Patrick Marcellin
    Service d hépatologie and INSERM CRB3, Hopital Beaujon, APHP, Universite Denis Diderot Paris 7, Clichy, France
    Gastroenterology 140:459-468.e1; quiz e14. 2011
    ..telaprevir, administered every 8 hours (q8h), combined with pegylated interferon (peginterferon) alfa-2a plus ribavirin significantly increased the rate of hepatitis C virus (HCV) eradication (sustained virologic response [SVR]) in ..
  46. ncbi Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases
    Seyed Moayed Alavian
    Research Center for Gastroenterology and Liver Disease, Baqiyatallah University of Medical Sciences, Tehran, Iran
    Liver Int 30:1173-80. 2010
    ..Peginterferon alpha and ribavirin is current standard anti-HCV therapy but there is little information about safety and efficacy of peginterferon ..
  47. ncbi Mechanisms of action of ribavirin against distinct viruses
    Jason D Graci
    Department of Biochemistry and Molecular Biology, The Pennsylvania State University, University Park, Pennsylvania, USA
    Rev Med Virol 16:37-48. 2006
    The nucleoside analogue ribavirin has antiviral activity against many distinct viruses both in vitro and in vivo. Five distinct mechanisms have been proposed to explain the antiviral properties of ribavirin...
  48. ncbi Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    Hepatology 38:75-85. 2003
    ..We assess the effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis. We analyzed 1,428 naïve patients included in a randomized trial...
  49. pmc IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection
    Chun Yen Lin
    Department of Gastroenterology and Hepatology, Linkou Medical Center, Chang Gung Memorial Hospital, Kweishan, Taoyuan, Taiwan
    PLoS ONE 6:e18322. 2011
    ..when treating patients of genotype-1 hepatitis C virus (GT1-HCV) chronic infection with pegylated interferon and ribavirin (PegIFN/RBV)...
  50. ncbi Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients
    Dong H Sinn
    Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    J Gastroenterol Hepatol 26:1374-9. 2011
    ..A single nucleotide polymorphism near the interleukin-28B (IL28B) gene has been shown to predict hepatitis C virus (HCV) treatment response. We aim to determine the role of the IL28B genotype in Asian patients...
  51. ncbi A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus
    Philippe Halfon
    Laboratoire Alphabio, Hopital Ambroise Pare, France
    Eur J Gastroenterol Hepatol 23:931-5. 2011
    ..The aim of this study was to determine whether a single IL-28B genotype SNP rs8099917 or rs12979860 determination is sufficient to predict treatment failure in patients with chronic HCV...
  52. ncbi [Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C]
    Heon Ju Lee
    Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea
    Korean J Hepatol 14:46-57. 2008
    This study compared the efficacy and safety of combined peginterferon alfa (PEG-IFN) and ribavirin with that of combined interferon alpha (IFN-alpha) and ribavirin, according to the treatment duration in Korean patients with chronic ..
  53. ncbi Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin
    Chung Feng Huang
    Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
    J Hepatol 56:34-40. 2012
    ..response (SVR, HCV RNA seronegative throughout 24 weeks of post-treatment follow-up) after 24 weeks peginterferon/ribavirin therapy. We explored the role of interleukin-28B genotype in identifying patients who responded to the regimen.
  54. ncbi IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1
    M Lindh
    Department of Infectious Diseases, University of Gothenburg, Gothenburg, Sweden
    J Viral Hepat 18:e325-31. 2011
    ..We conclude that the IL28B variability influences the antiviral efficiency of interferon/ribavirin therapy and has a strong impact on SVR, independently of traditional response predictors...
  55. pmc IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C
    Kazuaki Chayama
    Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN, Japan
    J Infect Dis 204:84-93. 2011
    Pegylated interferon, ribavirin, and telaprevir triple therapy is a new strategy expected to eradicate the hepatitis C virus (HCV) even in patients infected with difficult-to-treat genotype 1 strains, although adverse effects, such as ..
  56. pmc A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape
    Rubén Agudo
    Centro de Biologia Molecular Severo Ochoa CSIC UAM, Cantoblanco, Madrid, Spain
    PLoS Pathog 6:e1001072. 2010
    ..Previous studies with RNA viruses have documented that resistance to the mutagenic nucleoside analogue ribavirin (1-β-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide) is mediated by amino acid substitutions in the viral ..
  57. ncbi Peginterferon and ribavirin for chronic hepatitis C
    Jay H Hoofnagle
    Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA
    N Engl J Med 355:2444-51. 2006
  58. ncbi Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection
    Limin Chen
    Banting and Best Department of Medical Research, University of Toronto, Ontario, Canada
    Gastroenterology 128:1437-44. 2005
    Pegylated interferon (IFN)-alpha plus ribavirin is the most effective treatment of chronic hepatitis C but has unpleasant side effects and high costs. A large proportion of patients do not respond to therapy for reasons that are unclear...
  59. ncbi Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
    Ann D Kwong
    Vertex Pharmaceuticals, Cambridge, Massachusetts, USA
    Nat Biotechnol 29:993-1003. 2011
    ..infected with genotype 1 HCV, treatment with polyethylene glycol decorated interferon (peginterferon) α and ribavirin (PR) is associated with a low (40-50%) success rate, substantial treatment-limiting side effects and a long (48-..
  60. pmc Hepatitis C treatment: current and future perspectives
    Saira Munir
    National Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan
    Virol J 7:296. 2010
    ..Standard interferon and ribavirin remained a gold standard of chronic HCV treatment having 38-43% sustained virological response rates...
  61. ncbi Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
    Peter Ferenci
    Medical University of Vienna, Vienna, Austria
    J Hepatol 43:425-33. 2005
    ..Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy...
  62. ncbi Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
    Christophe Hezode
    Assistance Publique Hopitaux de Paris, Henri Mondor Hospital, University of Paris 12 and INSERM Unité 955, Creteil, France
    N Engl J Med 360:1839-50. 2009
    In patients with chronic infection with hepatitis C virus (HCV) genotype 1, treatment with peginterferon alfa and ribavirin for 48 weeks results in rates of sustained virologic response of 40 to 50%...
  63. ncbi Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 52:421-9. 2010
    ..core region of hepatitis C virus (HCV) genotype 1b can predict the response to pegylated interferon (PEG-IFN)/ribavirin combination therapy, but its impact on triple therapy of telaprevir/PEG-IFN/ribavirin is not clear...
  64. ncbi Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    N Engl J Med 360:257-67. 2009
    ..We evaluated the effect of Latino ethnic background on the response to treatment with peginterferon alfa-2a and ribavirin in patients infected with HCV genotype 1 who had not been treated previously.
  65. ncbi Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin
    L Valenti
    Department of Internal Medicine, Universita degli Studi, Fondazione Cà Granda IRCCS Ospedale Maggiore Policlinico, Milan, Italy
    Aliment Pharmacol Ther 35:1434-42. 2012
    ..Homozygosity for the PNPLA3 p.I148M polymorphism influences steatosis and fibrogenesis in chronic hepatitis C (CHC)...
  66. ncbi Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients
    Michael Boeckh
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Clin Infect Dis 44:245-9. 2007
    Respiratory syncytial virus infection of the upper airways may progress to fatal pneumonia in hematopoietic cell transplant recipients. The safety and efficacy of aerosolized ribavirin in preventing disease progression is unknown.
  67. ncbi Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response
    Conrado M Fernández-Rodríguez
    Hospital Universitario Fundacion Alcorcon, Madrid, Spain
    Am J Gastroenterol 105:2164-72; quiz 2173. 2010
    ..Patients with hepatitis C virus (HCV) cirrhosis are difficult to treat and have a high risk of liver decompensation or hepatocellular carcinoma. We sought to identify factors that could predict treatment response...
  68. ncbi Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6
    N H Nguyen
    Pacific Health Foundation, San Jose, CA, USA
    J Viral Hepat 17:691-7. 2010
    ..of 167 consecutive treatment-naïve Asian American patients treated with pegylated interferon (PEG IFN) plus ribavirin (RBV) at two community clinics in Northern California from 12/00 to 1/08...
  69. ncbi UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients
    P Ramachandran
    Department of Gastroenterology, Aberdeen Royal Infirmary, Aberdeen, UK
    Aliment Pharmacol Ther 35:647-62. 2012
    ..When used in combination with pegylated interferon and ribavirin, these drugs greatly improve sustained virological response rates in both treatment-naïve patients and patients ..
  70. ncbi Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b
    Yoshimasa Hashimoto
    Division of Frontier Medical Science, Department of Medical and Molecular Science, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, Hiroshima, Japan
    J Med Virol 83:981-8. 2011
    ..locus was recently reported to be a significant predictive factor of viral response to pegylated-interferon plus ribavirin combination therapy against chronic hepatitis C...
  71. ncbi Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin
    Kwangsoo Lyoo
    Department of Internal Medicine and WHO Collaborating Center on Viral Hepatitis, College of Medicine, The Catholic University of Korea, 137 040 Seoul, Republic of Korea
    J Clin Virol 52:363-6. 2011
    ..Single nucleotide polymorphisms (SNPs) near the IL28B gene have recently been described as predictors of antiviral therapy responses in patients with hepatitis C virus (HCV) genotype-1...
  72. pmc Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection
    Erik Alestig
    Department of Infection and Virology, University of Gothenburg, Gothenburg, Sweden
    BMC Infect Dis 11:124. 2011
    ..In the present study, the impact of these mutations on response kinetics and treatment outcome was explored in Caucasian patients...
  73. ncbi Treatment of chronic hepatitis C in Asia: when East meets West
    Ming Lung Yu
    Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
    J Gastroenterol Hepatol 24:336-45. 2009
    ..Currently, pegylated-interferon plus ribavirin is the standard of care...
  74. ncbi Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections
    Graham R Foster
    Queen Marys University of London, Blizard Institute of Cellular and Molecular Science, London, UK
    Gastroenterology 141:881-889.e1. 2011
    We evaluated antiviral activity of 2 weeks therapy with telaprevir alone, peginterferon alfa-2a and ribavirin (PR), or all 3 drugs (TPR) in treatment-naïve patients with chronic hepatitis C virus (HCV) genotype 2 or 3 infections.
  75. ncbi Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin
    Veronica D Gonzalez
    Center for Infection Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, 14186, Stockholm, Sweden
    Clin Immunol 128:46-56. 2008
    ..this expansion of unconventional CD56(-) NK cells rapidly reverted when HCV was suppressed by IFNalpha and ribavirin treatment, and was not seen in mono-infected control groups...
  76. pmc Outcome of sustained virological responders with histologically advanced chronic hepatitis C
    Timothy R Morgan
    Division of Gastroenterology, University of California Irvine, Irvine, CA, USA
    Hepatology 52:833-44. 2010
    ..15, 95% CI = 0.06-0.38) or HCC (HR = 0.19, 95% CI = 0.04-0.80) was significant for SVR compared to NR. Laboratory tests related to liver disease severity improved following SVR...
  77. ncbi Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin
    Ira M Jacobson
    Center for Study of Hepatitis C, Weill Cornell Medical College, New York, NY, USA
    Hepatology 56:567-75. 2012
    In comparison with peginterferon/ribavirin alone, boceprevir with peginterferon/ribavirin significantly improves sustained virological response (SVR) rates in patients with chronic hepatitis C virus (HCV) genotype 1 infections, but ..
  78. pmc Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype
    Xiaoyan Guo
    Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat Sen University, 600 Tian He Road, Guangzhou 510630, PR China
    Virol J 9:123. 2012
    The standard treatment for patients with chronic hepatitis C (CHC), pegylated interferon-α (PEG-IFN) plus ribavirin (RBV) does not provide a sustained virological response (SVR) in all patients...
  79. ncbi In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection
    Guofeng Zhang
    Department of Microbiology and Immunity, Nanjing Medical University, 140 Hanzhong Road, Nanjing, 210029, Jiangsu, China
    Arch Virol 157:669-79. 2012
    ..In this study, the activity of ribavirin and pleconaril against EV71 infection was evaluated in two models...
  80. pmc Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin
    Darryl Falzarano
    Disease Modeling and Transmission Unit, Hamilton, MT, USA
    Sci Rep 3:1686. 2013
    ..To determine an intervention strategy, the effect of interferon-α2b and ribavirin on nCoV isolate hCoV-EMC/2012 replication in Vero and LLC-MK2 cells was evaluated...
  81. ncbi Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients
    Jose A Mira
    Unidad de Enfermedades Infecciosas y Microbiología Clinica, Hospital Universitario de Valme, Seville, Spain
    AIDS 26:1721-4. 2012
    We assess the efficacy of pegylated interferon (peg-IFN) with ribavirin (RBV) and the predictors of sustained virological response (SVR) among HIV/hepatitis C virus genotype 4 (HCV-4)-coinfected patients. Thirty-nine (31...
  82. ncbi Viral error catastrophe by mutagenic nucleosides
    Jon P Anderson
    The Joseph Gottstein Memorial Cancer Research Laboratory, Department of Pathology, University of Washington, Seattle, Washington 98195, USA
    Annu Rev Microbiol 58:183-205. 2004
    ..in culture has been documented and has been postulated to be the mechanism for treatment of hepatitis C with ribavirin. We consider the viral dynamics involved in the formation of a quasispecies, the choice of mutagenic nucleoside ..
  83. ncbi ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients
    Hidenori Ochi
    Laboratory for Liver Diseases, RIKEN Center for Genomic Medicine, Hiroshima, Japan
    Gastroenterology 139:1190-7. 2010
    b>Ribavirin-induced anemia is one of the major causes of discontinuation and dose reduction during anti-hepatitis C virus therapy. Factors influencing this anemia, especially host genetic factors, are poorly understood...
  84. ncbi Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus
    Masayuki Saijo
    Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, Tokyo 208 0011, Japan
    Antiviral Res 66:159-63. 2005
    The activity of inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors, mizoribine and ribavirin, against severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) was determined by plaque reduction and yield ..
  85. ncbi Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients
    Itaru Ozeki
    Department of Gastroenterology, Sapporo Kosei General Hospital, North 3 East 8, Chuou ku, Sapporo, Hokkaido, 060 0033, Japan
    J Gastroenterol 46:929-37. 2011
    ..commonly observed as a side effect in a treatment with protease inhibitors combined with peginterferon alpha and ribavirin for hepatitis C virus infection...
  86. ncbi Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin
    Thomas Matthias Scherzer
    Department of Internal Medicine III, Medical University, Vienna, Austria
    Hepatology 54:1518-26. 2011
    ..in genotype 1/4 patients who received response-guided therapy with peginterferon alpha-2a 180 μg/week plus ribavirin 1,000/1,200 mg/day in a large, randomized, multicenter study...
  87. pmc Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses
    Jack T Nguyen
    Adamas Pharmaceuticals, Inc, Emeryville, California, United States of America
    PLoS ONE 7:e31006. 2012
    ..We describe a triple combination antiviral drug (TCAD) regimen composed of amantadine, oseltamivir, and ribavirin that is highly efficacious at reducing mortality and weight loss in mouse models of influenza infection...
  88. ncbi Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection
    B J Veldt
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
    Am J Transplant 8:2426-33. 2008
    ..24; CI 0.08-0.69, p = 0.008). In conclusion, although a cause and effect relationship cannot be established, treatment of recurrent HCV infection after liver transplantation is associated with a reduced risk of graft failure...
  89. ncbi IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection
    Amir Moghaddam
    Furst Medisinsk Laboratorium, Oslo, Norway
    Hepatology 53:746-54. 2011
    ..the IL28B gene, which code for interferon (IFN)-λ3, predict response to pegylated interferon-α (PEG-IFN) and ribavirin treatment in hepatitis C virus (HCV) genotype 1 infected patients...
  90. ncbi Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial
    Ira M Jacobson
    Weill Medical College of Cornell University, Center for the Study of Hepatitis C, New York Presbyterian Hospital, New York, NY 10021, USA
    Hepatology 46:971-81. 2007
    ..evaluated efficacy and safety of pegylated interferon (PEG-IFN) alfa-2b plus a flat or weight-based dose of ribavirin (RBV) in adults with chronic hepatitis C...
  91. ncbi Modelling how ribavirin improves interferon response rates in hepatitis C virus infection
    Narendra M Dixit
    Theoretical Biology and Biophysics, Theoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
    Nature 432:922-4. 2004
    ..Combination therapy with pegylated interferon and ribavirin, the latest treatment for HCV infection, elicits long-term responses in only about 50% of patients treated...
  92. ncbi Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4
    Stella De Nicola
    Centro AM e A Migliavacca, First Division of Gastroenterology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Universita degli Studi di Milano, Milan, Italy
    Hepatology 55:336-42. 2012
    ..are the strongest baseline predictors of a sustained virologic response (SVR) to peg-interferon (PegIFN) and ribavirin (Rbv) in patients with hepatitis C virus (HCV) genotype 1 infection...
  93. pmc Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study
    Nanna Hansen
    Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, 2650 Hvidovre, Denmark
    BMC Infect Dis 11:177. 2011
    The effect of peginterferon and ribavirin treatment on chronic hepatitis C virus (HCV) infection has been established in several controlled clinical studies...
  94. pmc Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1
    Charles D Howell
    University of Maryland School of Medicine, Program in Genetics and Genomic Medicine, Baltimore, MD, USA
    J Hepatol 56:557-63. 2012
    We studied the relationship between IL28B gene-related SNP rs12979860 and early viral kinetics (day 0-28) during peginterferon and ribavirin treatment, in 173 African Americans (AA) and 188 Caucasian Americans (CA) with HCV genotype 1.
  95. pmc Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Gastroenterology 139:1181-9. 2010
    ..functional variants in ITPA that cause inosine triphosphatase (ITPase) deficiency were shown to protect against ribavirin (RBV)-induced hemolytic anemia during early stages of treatment...
  96. ncbi Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir
    Fumitaka Suzuki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 53:415-21. 2011
    ..Polymorphisms of the inosine triphosphatase (ITPA) gene influence anemia during pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, but their effects during triple therapy with PEG-IFN, RBV, and telaprevir are not known...
  97. ncbi Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin
    Thomas Matthias Scherzer
    Medical University of Vienna, Internal Medicine III, Department of Gastroenterology and Hepatology, Austria
    J Hepatol 54:866-71. 2011
    ..This study analyzes the impact of these IL28B polymorphisms on early treatment response (weeks 2 and 4) and SVR in HCV genotype 3 patients...
  98. ncbi Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus
    Juan A Pineda
    Unit of Infectious Diseases, Hospital Universitario de Valme, Seville, Spain
    Clin Infect Dis 51:788-95. 2010
    Variation in the IL28B gene is associated with sustained virologic response (SVR) to pegylated interferon plus ribavirin in hepatitis C virus (HCV)-monoinfected patients with genotype 1...
  99. pmc IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients
    Ester Aparicio
    Fundacio irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain
    PLoS ONE 5:e13771. 2010
    ..rs8099917 SNP genotyping may be a valid pre-treatment predictor of which patients are likely to respond to treatment in this group of difficult-to-treat HCV/HIV-infected patients...
  100. pmc High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment
    Veronica D Gonzalez
    Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, 14186 Stockholm, Sweden
    J Virol 83:11407-11. 2009
    ..Interestingly, the suppression of HCV by pegylated alpha interferon and ribavirin treatment reduces activation...
  101. pmc Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients
    Maureen J Donlin
    Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St Louis, Missouri, United States of America
    PLoS ONE 5:e9032. 2010
    ..African American patients respond to interferon alpha-based therapy at about half the rate of Caucasian Americans. The effect of HCV's genetic variation on treatment outcome in both racial groups is poorly understood...

Research Grants74

  1. Lethal Mutagenesis as an Antiviral Strategy
    Craig Cameron; Fiscal Year: 2007
    ..of infections by RNA viruses classified as either category A, B or C pathogens consists of one compound, ribavirin. Ribavirin is the only broad-spectrum antiviral nucleoside employed clinically...
  2. Ubiquitous pollutant acrolein inhibits IFN?? antiviral signaling: relevance to HC
    Swati Joshi-Barve; Fiscal Year: 2013
    ..FDA approved standard of care for chronic hepatitis C is a combination of pegylated interferon-alpha (IFN1) and ribavirin. Unfortunately, this regimen is only effective in about 50% of patients, emphasizing the need for studies ..
  3. Roles for microRNA-122 in hepatitis C virus RNA amplification
    Peter Sarnow; Fiscal Year: 2013
    ..Current treatment is limited to a combination therapy of ribavirin and interferon 1. This therapy is expensive and ineffective in 50% of infected individuals...
  4. Heat Shock Protein Synthesis Inhibitor Treatment of Hepatitis C Viral Infection
    SAMUEL WHEELER FRENCH; Fiscal Year: 2013
    ..Current therapy consists of pegylated interferon-1 (PEG-IFN) and ribavirin (RBV)...
  5. Structure and Function of the Hepatitis C Virus Genome
    Peter Sarnow; Fiscal Year: 2013
    ..Current treatment is limited to co-treatment with ribavirin and interferon 1, a therapy that is expensive and ineffective in 50% of infected individuals...
  6. Hepatic Lipase and HCV Infection
    Tianyi Wang; Fiscal Year: 2010
    ..Combination therapy with polyethylene glycol modified IFN-a and ribavirin suppresses HCV replication in 40-80% of patients...
  7. Hepatocarcinogenesis Secondary to Hepatitis C
    Srikanta Dash; Fiscal Year: 2012
    ..Current therapy for chronic HCV infection, a combination of IFN-a and ribavirin, but only half of the patients can get rid of the virus infection by this regimen...
  8. Mechanistic Studies of HCV E2
    Joseph Marcotrigiano; Fiscal Year: 2013
    ..There is no vaccine available for HCV and the only treatment is pegylated interferon-? in combination with ribavirin, which leads to a sustained response in only 50% of patients...
  9. Recombinant life attenuated vaccine against Argentine hemorrhagic fever
    Slobodan Paessler; Fiscal Year: 2013
    ..vaccines in the US and current anti-arenavirus therapies being limited to the use of the nucleoside analogue ribavirin, which is only partially effective and can cause significant toxicity...
  10. Preventing lethal hemorrhagic fever caused by hantaviruses by preserving endothel
    ALAN L MUELLER; Fiscal Year: 2012
    ..We will also test Slit2N in conjunction with the anti-viral ribavirin in an effort to determine whether, as we hypothesize, Slit2N in combination with an anti-viral will result in ..
  11. Antiviral activity of leflunomide against respiratory syncytial virus
    WILLIAM WALDMAN; Fiscal Year: 2009
    ..No effective vaccine is currently available for prevention of RSV disease. Ribavirin, the only approved antiviral therapy, which must be administered by aerosol for 12 to 18 hours/day for 3 to 7 ..
  12. Hepatitis C and Tumor Suppressors in Hepatocellular
    Stanley M Lemon; Fiscal Year: 2011
    ..whether the proportion of cells displaying proliferation markers is reduced after standard-of-care peg-IFN/ribavirin therapy...
  13. Anti HCV Protease Activities of Metalloporphyrins
    Warren N Schmidt; Fiscal Year: 2013
    ..Current therapy for chronic HCV infection is alpha-interferon (IFN) and ribavirin (RBV) for 24-48 weeks, together with an approved protease inhibitor, depending on HCV genotype...
  14. Underlying Mechanisms of ApoE in HCV Infection and Assembly
    GUANGXIANG GEORGE LUO; Fiscal Year: 2013
    ..S. Pegylated interferon-a in combination with ribavirin is the only option for treatment of hepatitis C...
  15. Novel Screen to Identify Arenavirus Inhibitors
    Juan Lama; Fiscal Year: 2013
    ..Current anti-arenavirus therapies are limited to the use of the non-specific antiviral ribavirin (Rib), which is only partially efficient and associted with significant side effects...
  16. Targeting the processing of the arenavirus glycoprotein for anti-viral therapy.
    Juan C de la Torre; Fiscal Year: 2012
    ..No licensed anti-arenavirus vaccines are available, and current anti-arenavirus therapy is limited to the use of ribavirin, which is only partially effective and associated with severe side effects...
  17. Role of HCV Sequence Variation in Pathology
    John E Tavis; Fiscal Year: 2010
    ..HCV infection is treated with pegylated interferon ( plus ribavirin, but this fails in half of genotype 1 patients, the most common genotype in the USA...
  18. Preclinical Development of m102.4, a Human Anti-Hendra and Nipah Antibody
    Timothy R Fouts; Fiscal Year: 2013
    ..b>Ribavirin has been used against HeV and NiV with no effect. We have identified a fully human monoclonal antibody, m102...
  19. DINUCLEOTIDE ISOMER AS A NOVEL ANTIVIRAL
    Radhakrishnan P Iyer; Fiscal Year: 2010
    ..9200 is synergistic with other anti-HCV agents such as nucleoside analogs, interferon, protease inhibitors, and ribavirin. SB 9200 represents potentially the next generation anti-HCV therapeutic...
  20. Inflammation, Stress, and Social Behavior: Using Ecological Assessments and Model
    Charles Raison; Fiscal Year: 2012
    ..with chronic hepatitis C virus infection will be randomized to receive treatment with pegylated IFN-alpha plus ribavirin or to postpone treatment for 8 weeks...
  21. Hepatitis C Clinical Trial-Clinical Center
    Jules L Dienstag; Fiscal Year: 2009
    ..with chronic hepatitis C and advanced fibrosis who were nonresponders to prior therapy with peginterferon and ribavirin. Participants were stratified by stage of fibrosis [unreadable] 622 with fibrosis and 428 with cirrhosis...
  22. Single-cycle Infectious Candid#1 to Study Hemorrhagic Fever New World Arenavirus
    Luis Martinez-Sobrido; Fiscal Year: 2013
    ..by the lack of licensed vaccines and by current anti-arenavirus therapy limited to the off-label use of ribavirin, which is only partially effective and often associated with severe side effects...
  23. Interactions Between Hepatitis C and Serum Lipid Homeostasis
    KATHLEEN COREY; Fiscal Year: 2010
    ..Unfortunately, standard therapy with pegylated interferon (PEGIFN) and ribavirin (RBV) leads to a sustained virologic response (SVR) in only 50% of genotype 1 patients, the predominant form of ..
  24. Backbone Modified Peptide-nucleic Acids as Antiviral Agents Against Hepatitis C
    MIHAELA R MIHAILESCU; Fiscal Year: 2012
    ..The current therapy to treat HCV infections, which uses recombinant alpha interferon and ribavirin, is efficient only in less than 50% of the patients and chronically HCV infected patients can develop serious ..
  25. Evaluation of LASV Protective Immunity in Mice Using Reassortant Virus ML29
    MARCO AURELIO GOICOCHEA; Fiscal Year: 2010
    ..There currently exists no vaccine against LF, while the need for such a vaccine is ever increasing. Ribavirin, the only known treatment to be effective against LF early on after infection, is hard to come by in endemic ..
  26. Preparing for New Antivirals: Preferences for Treatment of Hepatitis C
    Liana Fraenkel; Fiscal Year: 2013
    ..Among those with genotype 1 who have been treated with pegylated-interferon and ribavirin, the rate of sustained virologic response (SVR) is only 20%...
  27. The role of innate immune evasion in hepatitis C virus infection
    YPE PETER DE JONG; Fiscal Year: 2013
    ..Current treatments based on interferon-1 and ribavirin fail to cure the majority of people chronically infected with genotype 1 HCV, and rapidly emerging resistance to ..
  28. Viral and Cellular Determinants of HCV Assembly
    GUANGXIANG GEORGE LUO; Fiscal Year: 2013
    ..Current standard therapy with pegylated interferon-? in combination with ribavirin only achieves limited (<50%) antiviral response and causes severe side effects...
  29. Advancing clemizole for hepatitis C: towards a pre-IND package
    Jeffrey S Glenn; Fiscal Year: 2010
    ..mutants will retain their sensitivity to protease inhibitors and standard of care (interferon/ribavirin) agents (i...
  30. Roles for RCK/DDX6 in hepatitis C virus pathogenesis and hepatocellular carcinoma
    Peter Sarnow; Fiscal Year: 2010
    ..Current treatment is limited to co-treatment with ribavirin and interferon , a therapy that is expensive and ineffective in 50% of infected individuals...
  31. Modeling different strategies to reduce the public health impact of the HCV/HIV e
    Viviane Dias Lima; Fiscal Year: 2013
    ..Currently, chronic HCV infection can only be treated with peginterferon alfa and ribavirin and sustained viral response is not achieved by the majority of patients...
  32. Antivirals for Hepatitis C Targeting Phosphoinositide Metabolism
    Michael A Gelman; Fiscal Year: 2013
    ..standard of care for HCV treatment is a 12-48 week (depending on genotype and response) course of peginterferon-ribavirin, which is costly, has multiple serious side effects, and is only 50-80% effective...
  33. Anti-interferon Activity of the Arenavirus Nucleoprotein
    Luis Martinez-Sobrido; Fiscal Year: 2012
    ..No licensed anti-arenavirus vaccines are available, and current anti-arenavirus therapy is limited to the use of ribavirin, which is only partially effective and often associated with severe side effects...
  34. Quantitation and Genotyping of HCV RNA by Time Resolved Lanthanide Luminescence
    Andrew M Arsham; Fiscal Year: 2013
    ..Current standard-of-care combination antiviral therapy (ribavirin/peg-interferon) eradicates HCV in many patients, while newly FDA-approved HCV-specific therapies greatly ..
  35. Hepatitis C Virus and Hepatocellular Carcinoma
    Srikanta Dash; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Interferon alpha (IFN-[unreadable]) along with ribavirin is the standard treatment for patients with chronic HCV infection but this therapy is unable to clear the virus in the majority of patients...
  36. The Molecular Mechanism of Antibody Neutralization of Hepatitis C Virus
    Michelle Sabo; Fiscal Year: 2013
    ..Currently, there is no vaccine for HCV and the treatment regimen, pegylated Interferon-?2b and ribavirin, is only effective in ~50% of patients...
  37. A Novel Method of Generating Hepatitis C Virus-Like Particles using Lentivirus
    Boro Dropulic; Fiscal Year: 2009
    ..available and the current standard of care, a combination of Pegylated-Interferon alpha and the antiviral drug Ribavirin, is effective in only about 50% of patients completing therapy, is lengthy, and is often poorly tolerated...
  38. Cyclophilins, Cyclophilin Inhibitors and Hepatitis C
    PHILIPPE ANDRE GALLAY; Fiscal Year: 2013
    ..Current therapy for patients with chronic HCV infection includes high doses of IFN in combination with ribavirin. However, success rates remain low (around 50% of treated patients depending on genotype)...
  39. Collaborative Integration of HCV Molecular Virology and Mathematical Modeling
    Susan L Uprichard; Fiscal Year: 2013
    ..is available and only a subset of infected patients respond to the current treatment of interferon (IFN) plus ribavirin. Statistics predict that without improved therapeutics one million people in the US will suffer from HCV-related ..
  40. Dissecting eIF4E dependent mRNA export
    Katherine L B Borden; Fiscal Year: 2013
    ..We found that inhibition of eIF4E function by introduction of a physical mimic of the m7G cap, ribavirin, leads to inhibition of eIF4E's survival and proliferative activities, and is associated with clinical ..
  41. Mentoring Junior Faculty: Viral hepatitis Clinical Research
    Michael W Fried; Fiscal Year: 2013
    ..More than half of patients undergoing treatment with peginterferon and ribavirin for chronic hepatitis C can achieve a sustained virological response...
  42. Concentration-Controlled Ribavirin for the Treatment of Patients with Chronic HVC
    JENNIFER JUSTICE KISER; Fiscal Year: 2013
    ..Through the study proposed, the candidate will use pharmacokinetics (PK) to guide dosing decisions with ribavirin, generate preliminary data on intracellular ribavirin concentrations, and become poised to apply PK techniques ..
  43. Selection of the Optimal Nucleoside Triphosphate Mimic Prodrug Inhibitor of HCV R
    PHILLIP DAN COOK; Fiscal Year: 2011
    ..Beyond the limited efficiency combination treatment of 1-interferon (native or pegylated) and the nucleoside Ribavirin, which was introduced in 1990, there has not been another drug registered in the following 20 years...
  44. Neopterin and kynurenine as predictors of depression risk and antiviral efficacy
    Gregory F Oxenkrug; Fiscal Year: 2013
    ..and cost-effective methods predicting the major outcomes of IFN-alpha therapy (alone and in combination with ribavirin or protease inhibitors) of HCV (and other conditions treatable with IFN-alpha, e.g...
  45. Hepatitis C Virus Quasispecies in the Resistance to Antiviral Therapy
    Xiaofeng Fan; Fiscal Year: 2012
    ..Currently, optimal antiviral therapy with pegylated interferon-alpha plus ribavirin, cures ~50% of patients infected with HCV genotype 1 and ~80% of patients infected with HCV genotypes 2 and 3...
  46. Understanding human neutralizing antibodies to hepatitis C virus
    Mansun Law; Fiscal Year: 2013
    ..The immunosuppressed liver transplant recipients tolerate the side effects of IFN-[unreadable] and ribavirin poorly and therefore new strategies for prevention and/or treatment of HCV in the transplant setting are ..
  47. Interferon modulation of cellular microRNAs in the Hepatitis C antiviral defense
    Michael David; Fiscal Year: 2010
    ..only approved therapy for treatment of chronic HCV infection is a combination of type I interferon (IFNa/p) and ribavirin with a response to treatment between 42% and 82% sustained viral clearance...
  48. Tight Junction: Gate to HCV Tropism, Therapeutics and Pathogenesis
    Tianyi Wang; Fiscal Year: 2013
    ..there is no vaccine available to prevent the infection, and combination therapy with pegylated IFN-a and ribavirin is only effective in 40-80% of patients and has severe side effects...
  49. Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy
    Charles H Hinkin; Fiscal Year: 2012
    ..The main treatment for HCV is pegylated interferon alfa and ribavirin (PEG-IFN/RBV)...
  50. Protease-resistant D-peptide inhibitors of RSV entry
    Brett D Welch; Fiscal Year: 2013
    ..For the most acute cases, ribavirin, a broad-range antiviral with questionable efficacy and significant safety issues can be used, though it is not ..
  51. Phase I/II Trials of Silymarin for Chronic Liver Diseases Data Coordinating Cente
    Steven H Belle; Fiscal Year: 2011
    ..for treating patients with chronic hepatitis C virus who have contraindications to therapy with interferon and ribavirin. The current lack of therapy for non-alcoholic steatohepatitis provides silymarin with a potential role in ..
  52. Antiviral Role of APOBEC3 in HIV/HCV Coinfected Patients
    SATISH KUMAR PILLAI; Fiscal Year: 2012
    ..The current standard of treatment for HCV infection is combination therapy with ribavirin and the immunomodulatory cytokine interferon-a (IFN-a)...
  53. Metallodrugs Targeting HCV Protease
    ADA S COWAN; Fiscal Year: 2010
    ..Current therapy uses a combination of interferon and ribavirin. Treatment is expensive and not very effective. Moreover, it does not clear the virus from the patient...
  54. NK/DC Cross-Talk and Antiviral Response
    Luis J Montaner; Fiscal Year: 2011
    DESCRIPTION (provided by applicant): The mechanisms of HCV eradication following IFN-?/ribavirin therapy in HCV/HIV-1 co-infection or HCV mono-infection remain unclear...
  55. Psychoeducation for HCV and Alcohol Behaviors
    Carol S North; Fiscal Year: 2010
    ..to be effective, yet physical and psychiatric side effects induced by current medications (interferon and ribavirin) undermine patient motivation and consistency...
  56. The Molecular Basis of Hepatitis C Clinical Resistance to Interferon Therapy
    PHILLIP SOON HO PANG; Fiscal Year: 2010
    ..only ~50 percent of patients chronically-infected with HCV respond to combination therapy with interferon and ribavirin, the current standard of care...
  57. Structure and Function of the Hepatitis C Virus Genome
    PETER contact SARNOW; Fiscal Year: 2010
    ..Current treatment is limited to co-treatment with ribavirin and interferon 1, a therapy that is expensive and ineffective in 50% of infected individuals...
  58. HCV TREATMENT IN AFRICAN AMERICANS VS NON HISPANIC WHIT*
    Lennox Jeffers; Fiscal Year: 2005
    ..to evaluate the efficacy of 40 kDa Pegylated interferon alfa-2a (Peginterferon alfa-2a) in combination with Ribavirin in the treatment of genotype-1 chronic hepatitis C (HCV, genotype-1) in African American men and women as ..
  59. VIRAHEP-C Clinical Center
    Anna Lok; Fiscal Year: 2005
    ..Treatment with combination of IFN + and ribavirin for 24 or 48 weeks results in SVR rates of up to 35 to 43% respectively...
  60. ANTIVIRAL DRUG DELIVERY WITH LYOPHILIZED PLATELETS
    Thomas Fischer; Fiscal Year: 2004
    ..Our strategy is to use rehydrated, lyophilized (RL) platelets to deliver ribavirin to the macrophages of the reticuloendothelial system (RES) that are involved in the initial stage of viral ..
  61. Resistance to Antiviral Therapy in Chronic Hepatitis C
    Norah Terrault; Fiscal Year: 2005
    ..Response rates appear to higher with combination interferon plus ribavirin than with interferon monotherapy...
  62. Interferon-gamma To Treat Chronic HCV Infection
    Andrew Muir; Fiscal Year: 2002
    ..Treatment with interferon-alpha and ribavirin leads to a sustained response in the minority of patients, and many patients may not be eligible for treatment ..
  63. ZIDOVUDINE METABOLISM: REBRETRON TREATED HUMAN PATIENTS
    Jose Rodriguez; Fiscal Year: 2003
    ..The central hypothesis to be tested is that REBETRON (ribavirin + interferon alpha) will antagonize in vivo with ZDV, diminishing the formation of ZDV intracellular metabolites ..
  64. Syrian Hamster as a Permissive Model for Testing Anti-Adenovirus Drugs
    William Wold; Fiscal Year: 2007
    ..There are no anti-viral drugs approved to treat these Ad infections. Cidofovir and ribavirin are used in some cases, but it is not known whether they are effective because they have not been studied in a ..
  65. Engineered 3-D Human Liver Tissue for Hepatitis Studies
    BRIAN NAUGHTON; Fiscal Year: 2004
    ..The current standard of care employs a combination of interferon-a and ribavirin, but only half of the patients treated show a sufficient antiviral response...
  66. Stabilize Addiction/Affect, Begin Inmates' Interferon for HCV of Liver (STAABIHL)
    Peter Friedmann; Fiscal Year: 2009
    ..and psychiatric symptoms are leading causes of denial or discontinuation of pegylated interferon (peglFN) plus ribavirin (RBV) therapy...
  67. Mechanisms of Action of Silymarin for Hepatitis C
    STEPHEN POLYAK; Fiscal Year: 2009
    ..The only approved treatment for chronic hepatitis C is interferon (IFN) and ribavirin, which only cures about 50% of infected patients...